Abstract Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a
proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number …

Abstract The phosphoinositide 3-kinase (PI3K) pathway is one of the most frequently
mutated pathways in cancer, and is actively being pursued as a therapeutic target. Despite …

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …

Gastric and esophageal cancers represent a major global cancer burden and novel
approaches are needed. Despite recent improvements in outcomes with trastuzumab and …

Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small …

Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …

Cancers originating in the esophagus or esophagogastric junction constitute a major global
health problem. Esophageal cancers are histologically classified as squamous cell …

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …

Background & Aims It has been a challenge to select treatment for patients with pancreatic
ductal adenocarcinomas (PDACs) based on genome alterations. We performed targeted …